← GLP-1 receptor agonists × glycemic control

TrialDiabetes, obesity & metabolism2016

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.

T S Bailey et al.PubMed ↗Full text ↗Publisher ↗

Liraglutidelooks good hereLower HbA1c from baseline to week 26, lower body weight.Randomised, small.

What the trial testedrandomised · 407 people · 2016

Randomised vs continued sitagliptin

Probably lowered HbA1c from baseline to week 26

−0.61percentage points−0.82 to −0.40

liraglutide vs continued sitagliptin

As reported

difference −0.61 %, 95% CI −0.82 to −0.40 · the paper's word: change in HbA1c from baseline to week 26

Randomised vs continued sitagliptin

Probably lowered body weight

−1.67kg−2.34 to −0.99

liraglutide vs continued sitagliptin

As reported

difference −1.67 kg, 95% CI −2.34 to −0.99 · the paper's word: change in body weight

Who was studied, and how

407people with obesity, in this paper

The trial randomly assignedassigned by chance

liraglutide

continued sitagliptin

Probably lowered HbA1c from baseline to week 26−0.61

Probably lowered body weight−1.67

randomised

the abstract, start to end

… mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; …

… liraglutide [-3.31 kg vs. -1.64 kg; ETD: -1.67 kg (95% CI -2.34 to -0.99; …

← favours treatmentfavours comparator →

could be chance

Change in HbA1c from baseline to week 26liraglutide vs continued sitagliptin

−0.61−0.82 to −0.40

Change in body weightliraglutide vs continued sitagliptin

−1.67−2.34 to −0.99

GLP-1 receptor agonistsGlycemic controlBody weight & composition

1 / 4

20 papers cite it

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

this paperpooled ittrialcites it

The trial

NCT01907854phase 4407 enrolled2013